4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2…
4D-125 was well tolerated in all patients treated to-date (n=8), with no dose-limiting toxicities, no serious adverse events and no chronic inflammationClinical activity observed through…